Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open, Single-dose, 3-treatment, 3-period, 6-sequence Crossover Study in Healthy Male Subjects to Evaluate the Pharmacokinetics of GLA5PR GLARS-NF1 Tablet 150mg and LYRICA® Capsule 75mg

NCT02326987 is registered in ClinicalTrials.gov with GL Pharm Tech Corporation as lead sponsor.

NCT NCT02326987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02326987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open, Single-dose, 3-treatment, 3-period, 6-sequence Crossover Study in Healthy Male Subjects to Evaluate the Pharmacokinetics of GLA5PR GLARS-NF1 Tablet 150mg and LYRICA® Capsule 75mg
Lead sponsor
GL Pharm Tech Corporation
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2013
Completion date
November 30, 2013
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy